Compare AVNW & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | ZNTL |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.7M | 289.0M |
| IPO Year | 2007 | 2020 |
| Metric | AVNW | ZNTL |
|---|---|---|
| Price | $19.27 | $2.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $32.75 | $7.44 |
| AVG Volume (30 Days) | 88.4K | ★ 1.3M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.00 | 18.03 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $243,858,000.00 | N/A |
| Revenue This Year | $5.50 | N/A |
| Revenue Next Year | $6.59 | N/A |
| P/E Ratio | $98.55 | ★ N/A |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $13.92 | $1.21 |
| 52 Week High | $27.02 | $6.95 |
| Indicator | AVNW | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 33.89 |
| Support Level | $18.70 | $2.09 |
| Resistance Level | $19.65 | $2.76 |
| Average True Range (ATR) | 0.82 | 0.17 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 25.10 | 17.35 |
Aviat Networks Inc manufacture and sell a range of wireless transport and access networking products, solutions and services to two principal customer types. Communications Service Providers (CSPs): These include mobile and fixed telecommunications network operators, broadband and internet service providers and network operators which generate revenues from the communications services. Private network operators: These are customers which do not resell communications services but build networks for reasons of economics, autonomy, and/or security to support a wide variety of mission critical performance applications. Examples include federal, state and local government agencies, transportation agencies, energy and utility companies, public safety agencies and broadcast network operators.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.